Stock Scorecard



Stock Summary for BioXcel Therapeutics Inc (BTAI) - $2.86 as of 3/28/2024 5:35:30 PM EST

Total Score

4 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BTAI

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BTAI

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BTAI

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for BTAI

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for BTAI

BioXcel Therapeutics Announces $25 Million Registered Direct Offering 3/25/2024 11:00:00 AM
BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine - BioXcel Therapeutics ( NASDAQ:BTAI ) 3/15/2024 11:00:00 AM
BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine 3/15/2024 11:00:00 AM
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 3/12/2024 11:00:00 AM
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 - BioXcel Therapeutics ( NASDAQ:BTAI ) 3/1/2024 12:00:00 PM
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 3/1/2024 12:00:00 PM
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies - BioXcel Therapeutics ( NASDAQ:BTAI ) , Bristol-Myers Squibb ( NYSE:BMY ) 2/14/2024 1:30:00 PM
BioXcel Therapeutics Announces Termination of Proposed Public Offering 2/13/2024 2:00:00 PM
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer ( SCNC ) 2/12/2024 12:14:00 PM
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - BioXcel Therapeutics ( NASDAQ:BTAI ) 2/10/2024 2:00:00 AM

Financial Details for BTAI

Company Overview

Ticker BTAI
Company Name BioXcel Therapeutics Inc
Country USA
Description BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/6/2024

Stock Price History

Last Day Price 2.86
Last Day Price Updated 3/28/2024 5:35:30 PM EST
Last Day Volume 531,733
Average Daily Volume 1,071,809
52-Week High 29.56
52-Week Low 1.91
Last Price to 52 Week Low 49.74%

Valuation Measures

Trailing PE N/A
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -5.70
Free Cash Flow Ratio 1.34
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 2.65
Total Cash Per Share 2.13
Book Value Per Share Most Recent Quarter -1.89
Price to Book Ratio 3.97
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 63.37
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 30,576,700
Market Capitalization 87,449,362
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -8.02%
Reported EPS 12 Trailing Months -6.15
Reported EPS Past Year -6.15
Reported EPS Prior Year -5.91
Net Income Twelve Trailing Months -179,053,000
Net Income Past Year -179,053,000
Net Income Prior Year -165,757,000
Quarterly Revenue Growth YOY 58.00%
5-Year Revenue Growth 0.00%

Balance Sheet

Total Cash Most Recent Quarter 65,221,000
Total Cash Past Year 65,221,000
Total Cash Prior Year 193,725,000
Net Cash Position Most Recent Quarter -138,057,000
Net Cash Position Past Year -138,057,000
Long Term Debt Past Year 203,278,000
Long Term Debt Prior Year 194,488,000
Total Debt Most Recent Quarter 203,278,000
Equity to Debt Ratio Past Year -0.39
Equity to Debt Ratio Most Recent Quarter -0.39
Total Stockholder Equity Past Year -56,508,000
Total Stockholder Equity Prior Year 76,775,000
Total Stockholder Equity Most Recent Quarter -56,508,000

Options

Put/Call Ratio 1.07
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.11
MACD Signal -0.08
20-Day Bollinger Lower Band 2.15
20-Day Bollinger Middle Band 3.10
20-Day Bollinger Upper Band 4.06
Beta 0.42
RSI 39.79
50-Day SMA 7.97
200-Day SMA 24.48

System

Modified 3/27/2024 8:05:32 PM EST